Surrozen Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 2.66, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Surrozen Inc in Jun 30 2026 quarter, has decreased to 137 days, compared to 178 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 472 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 3010 to 3318.

What is Receivable Turnover Ratio?
What is Surrozen Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

SRZN Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	115.8 %	134.74 %	145.22 %	-81 %	9.71 %
Y / Y Revenue Change	408.65 %	408.65 %	-19.39 %	-90.17 %	-
Receivable Turnover Ratio (TTM)	2.66	2.05	1.18	1.64	2.7
SRZN's Total Ranking	# 3318	# 3010	# 2643	# 3362	# 3003
Accounts Receivable average collection period days	137	178	309	223	135
Seq. Receivable Change	0 %	0 %	115.8 %	0 %	8.78 %
Seq. Revenue Change	0 %	846.97 %	-46.29 %	0 %	0 %

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 49
Healthcare Sector	# 473
Overall Market	# 3318

Receivable Turnover Ratio Statistics
High	Average	Low
0.16	0.08	0.03
(Jun 30 2025)

SRZN Company Profile • Back to SRZN Efficiency Comparisons • Compare SRZN Receivables Turnover Ratio to its Competitors

Financial Statements
Surrozen Inc 's Accounts Receivable	$ 5 Millions	Visit SRZN's Balance sheet
Surrozen Inc 's Sales TTM	$ 12 Millions	Visit SRZN's Income Statement
Sources of SRZN's Revenues		Visit SRZN's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
SRZN's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
SRZN's Growth Rates	SRZN's Roa	SRZN's Inventory Turnover Ratio	SRZN's Dividend Comparisons
SRZN's Profitability Ratios	SRZN's Roi	SRZN's Asset Turnover Ratio	SRZN's Dividend Growth
SRZN's Valuation Ratios	SRZN's Roe	SRZN's Financial Strength Ratios	SRZN's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Syndax Pharmaceuticals Inc	6.32	$ 252.004 Millions	$ 39.902 Millions
Nuwellis Inc	6.28	$ 9.013 Millions	$ 1.435 Millions
Puma Biotechnology Inc	6.27	$ 231.244 Millions	$ 36.902 Millions
Absci Corp	6.24	$ 1.561 Millions	$ 0.250 Millions
Insulet Corporation	6.24	$ 3,053.400 Millions	$ 489.200 Millions
Perrigo Company Plc	6.22	$ 4,144.000 Millions	$ 666.050 Millions
Maxcyte inc	6.22	$ 31.051 Millions	$ 4.994 Millions
Cue Biopharma Inc	6.21	$ 37.654 Millions	$ 6.064 Millions
Heartflow Inc	6.20	$ 210.791 Millions	$ 33.999 Millions
Omada Health Inc	6.20	$ 308.445 Millions	$ 49.770 Millions
Vertex Pharmaceuticals Inc	6.19	$ 12,587.200 Millions	$ 2,032.400 Millions
Orthofix Medical Inc	6.17	$ 833.344 Millions	$ 135.037 Millions
Harvard Bioscience Inc	6.16	$ 88.164 Millions	$ 14.306 Millions
Genedx Holdings Corp	6.16	$ 455.446 Millions	$ 73.962 Millions
Gilead Sciences Inc	6.15	$ 30,457.000 Millions	$ 4,951.000 Millions
Integra Lifesciences Holdings Corp	6.14	$ 1,647.666 Millions	$ 268.153 Millions
Zoetis Inc	6.13	$ 9,517.000 Millions	$ 1,552.000 Millions
Interpace Biosciences Inc	6.12	$ 36.519 Millions	$ 5.963 Millions
Xeris Biopharma Holdings Inc	6.12	$ 335.414 Millions	$ 54.800 Millions
Treace Medical Concepts Inc	6.12	$ 205.307 Millions	$ 33.551 Millions
Zevra Therapeutics Inc	6.09	$ 128.855 Millions	$ 21.172 Millions
Aquestive Therapeutics Inc	6.08	$ 54.087 Millions	$ 8.891 Millions
Femasys Inc	6.08	$ 2.299 Millions	$ 0.378 Millions
Sharps Technology Inc	6.07	$ 1.960 Millions	$ 0.323 Millions
Lakeland Industries Inc	6.07	$ 190.961 Millions	$ 31.455 Millions
Labcorp Holdings Inc	6.05	$ 14,348.000 Millions	$ 2,370.300 Millions
Monte Rosa Therapeutics Inc	6.02	$ 28.727 Millions	$ 4.774 Millions
Capsovision Inc	5.98	$ 12.804 Millions	$ 2.140 Millions
Sera Prognostics Inc	5.96	$ 0.070 Millions	$ 0.012 Millions
Msa Safety Inc	5.95	$ 1,946.916 Millions	$ 327.189 Millions

Date modified: 2026-09-08T01:25:43+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.